Teva Pharmaceutical Industries Limited (TEVA) announced the completion of its acquisition of Emalex Biosciences for a consideration of $700 million, with the potential for up to an additional $200 million in commercial milestone payments, among other contingent payments.
The acquisition adds Ecopipam, an investigational asset for pediatric Tourette syndrome, to Teva's pipeline.
Ecopipam is an investigational, selective dopamine antagonist designed to block dopamine signaling at the D1 receptor, developed to treat repetitive and compulsive behaviors associated with Tourette syndrome. The drug has received orphan drug designation and fast track designation from the FDA for treating pediatric patients with Tourette syndrome.
The drug was successfully evaluated in a Phase 3 trial, which met the primary efficacy endpoint by reducing relapse time for pediatric patients treated with ecopipam. It was also found to be generally well-tolerated.
The New Drug Application for Ecopipam in pediatric Tourette syndrome is expected to be submitted in the second half of 2026.
Teva shares closed on Wednesday at $33.58, down 2.53%. In the pre-market the shares are trading at $33.99, up 1.16%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.